Wave Life Sciences Shares Plunge 50% Despite Positive Obesity Drug Trial Data

Wave Life Sciences (WVE) shares collapsed by 50% in a single session following the release of data from the INLIGHT Phase 1 clinical trial for its obesity treatment, WVE-007. While the data showed a 14% reduction in visceral fat at a 240 mg dosage, two Wall Street firms responded by cutting their price targets for the company. The market's negative reaction pushed the stock below its 200-day moving average, triggering significant algorithmic selling pressure. Despite the plunge, Oppenheimer analyst Cheng Li characterized the decline as a 'generational' investment opportunity, noting the stock's 60% year-to-date drop. The event underscores the intense competition in the obesity drug market and the inherent volatility of the biotech sector.

Sources:invezz.comfiercebiotech.cominvesting.comgurufocus.comrollingout.comstocktwits.comuk.investing.comtickeron.comau.investing.com247wallst.com